Efficacy of lipid-lowering and anti-inflammatory effects of statins sequential therapy in coronary ;heart disease patients undergoing elective PCI
10.3969/j.issn.1004-8812.2014.04.006
- VernacularTitle:他汀序贯疗法在择期经皮冠状动脉介入治疗患者中降脂和抗炎作用的疗效观察
- Author:
Shao WANG
;
Haitao ZHANG
;
Chaozhong LIU
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
Sequential therapy;
Anti-inlfammatory
- From:
Chinese Journal of Interventional Cardiology
2014;(4):230-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the inlfuence and safety of early atorvastatin sequential therapy in coronary heart disease (CHD) patients underdoing elective percutaneous coronary intervention on selected indicators of inflammation and serum lipids. Methods A total of 88 CHD patients who got ready to receive the elective percutaneous coronary intervention (PCI) were divided in two groups at random:The sequential dose group was called group A (atorvatatin 80mg as loading dose ,40 mg/d for 1 month after PCI and 20 mg/d subsequently, n=43), and the ordinary dose group was called group B ( atorvastatin 20 mg/d, n=45). During the follow-up, blood samples were taken at baseline, 3 days,1 month, 3 months and 6 months for myeloperoxidase (MPO), matrix metalloproteinase-9(MMP-9), serum lipids, serum alanine aminotransferase (ALT), glutamyl endopeptidase (GGT) and creatine kinase (CK) levels. Main adverse cardiac events and adverse effects were also analyzed. Results Compared with the baseline, the level of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) was signiifcantly decreased in both two groups after treatment (P < 0.05). The LDL-C and TC in both groups were all decreased after treatment, and the degree of LDL-C and TC decreased at 3 days had signiifcant differences between the two groups (TC:26.6%vs. 14.0%;LDL-C:36.9%vs. 19.4%, both P<0.05). The degree of LDL-C decreased at 1 month between the two groups also had signiifcant differences (45.0%vs. 26.9%;P<0.05). The changes in LDL-C and TC level were also signiifcantly different between the two groups at 3 and 6 months (P<0.05). While TG and HDL-C remained unchanged. MMP-9 and MPO were both reduced post medication compared to pre-treatment levels (P<0.05). MPO was decreased signiifcantly in group A after treatment (F=18.455, P=0.000). And the same differences in group B were also signiifcant (P < 0.05). MPO post medication between the 2 groups were not significantly different (P > 0.05). Reduction in MMP-9 also showed signiifcant in both groups after treatment (group A:F=46.911, P=0.00;group B:F=19.156, P=0.00). The adverse effects had no signiifcant differences between the 2 groups (P>0.05). Conclusions The atorvastatin sequential theapy in CHD patients undergoing elective percutaneous coronary intervention could decrease serum lipids signiifcantly. Pretreatment with atorvastatin for patients undergoing PCI could inhibit inlfammation. The MACE and adverse effects were similar between the two groups.
